Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer

Huiyuan Wang, Feng Li, Chengan Du, Huixin Wang, Ram I Mahato, Yongzhuo Huang

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Our objective was to design a polymeric micelle-based doxorubicin and lapatinib combination therapy for treating multidrug resistant (MDR) breast cancers. Poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonylpropylene carbonate) (PEG-PBC) polymers were synthesized for preparing doxorubicin and lapatinib loaded micelles using a film dispersion method. Micelles were characterized by determining critical micelle concentration (CMC), particle size distribution, and drug loading. The anticancer effects were determined in vitro with MTT assays as well as with lactate dehydrogenase (LDH) release studies. In addition, the cellular uptake of drug-loaded micelles was determined with fluorescence microscopy and flow cytometry. Finally, in vivo anticancer activity and tolerance of developed formulations were evaluated in resistant breast tumor bearing mice. PEG5K-PBC7K polymer synthesized in this study had a low CMC value (1.5 mg/L) indicating an excellent dynamic stability. PEG-PBC micelles could efficiently load both doxorubicin and lapatinib drugs with a loading density of 21% and 8.4%, respectively. The mean particle size of these micelles was 100 nm and was not affected by drug loading. The use of lapatinib as an adjuvant sensitized drug resistant MCF-7/ADR cells to doxorubicin treatment. Cellular uptake studies showed enhanced doxorubicin accumulation in MCF-7/ADR cells in the presence of lapatinib. The doxorubicin and lapatinib combination therapy showed a significant decrease in tumor growth compared to doxorubicin monotherapy. In conclusion, we have developed PEG-PBC micelle formulations for the delivery of doxorubicin and lapatinib. The combination therapy of doxorubicin plus lapatinib has a great potential for treating MDR breast cancer.

Original languageEnglish (US)
Pages (from-to)2600-2611
Number of pages12
JournalMolecular Pharmaceutics
Volume11
Issue number8
DOIs
StatePublished - Aug 4 2014

Fingerprint

Nanomedicine
Micelles
Doxorubicin
Breast Neoplasms
Pharmaceutical Preparations
MCF-7 Cells
Particle Size
Polymers
lapatinib
Ethylene Glycol
Carbonates
L-Lactate Dehydrogenase
Fluorescence Microscopy
Flow Cytometry
Therapeutics

Keywords

  • breast cancer
  • combination therapy
  • doxorubicin
  • lapatinib
  • multidrug resistance
  • nanomedicine
  • polymeric micelles

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer. / Wang, Huiyuan; Li, Feng; Du, Chengan; Wang, Huixin; Mahato, Ram I; Huang, Yongzhuo.

In: Molecular Pharmaceutics, Vol. 11, No. 8, 04.08.2014, p. 2600-2611.

Research output: Contribution to journalArticle

Wang, Huiyuan ; Li, Feng ; Du, Chengan ; Wang, Huixin ; Mahato, Ram I ; Huang, Yongzhuo. / Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer. In: Molecular Pharmaceutics. 2014 ; Vol. 11, No. 8. pp. 2600-2611.
@article{ecb4c24602594ba285af63b645af524c,
title = "Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer",
abstract = "Our objective was to design a polymeric micelle-based doxorubicin and lapatinib combination therapy for treating multidrug resistant (MDR) breast cancers. Poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonylpropylene carbonate) (PEG-PBC) polymers were synthesized for preparing doxorubicin and lapatinib loaded micelles using a film dispersion method. Micelles were characterized by determining critical micelle concentration (CMC), particle size distribution, and drug loading. The anticancer effects were determined in vitro with MTT assays as well as with lactate dehydrogenase (LDH) release studies. In addition, the cellular uptake of drug-loaded micelles was determined with fluorescence microscopy and flow cytometry. Finally, in vivo anticancer activity and tolerance of developed formulations were evaluated in resistant breast tumor bearing mice. PEG5K-PBC7K polymer synthesized in this study had a low CMC value (1.5 mg/L) indicating an excellent dynamic stability. PEG-PBC micelles could efficiently load both doxorubicin and lapatinib drugs with a loading density of 21{\%} and 8.4{\%}, respectively. The mean particle size of these micelles was 100 nm and was not affected by drug loading. The use of lapatinib as an adjuvant sensitized drug resistant MCF-7/ADR cells to doxorubicin treatment. Cellular uptake studies showed enhanced doxorubicin accumulation in MCF-7/ADR cells in the presence of lapatinib. The doxorubicin and lapatinib combination therapy showed a significant decrease in tumor growth compared to doxorubicin monotherapy. In conclusion, we have developed PEG-PBC micelle formulations for the delivery of doxorubicin and lapatinib. The combination therapy of doxorubicin plus lapatinib has a great potential for treating MDR breast cancer.",
keywords = "breast cancer, combination therapy, doxorubicin, lapatinib, multidrug resistance, nanomedicine, polymeric micelles",
author = "Huiyuan Wang and Feng Li and Chengan Du and Huixin Wang and Mahato, {Ram I} and Yongzhuo Huang",
year = "2014",
month = "8",
day = "4",
doi = "10.1021/mp400687w",
language = "English (US)",
volume = "11",
pages = "2600--2611",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "8",

}

TY - JOUR

T1 - Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer

AU - Wang, Huiyuan

AU - Li, Feng

AU - Du, Chengan

AU - Wang, Huixin

AU - Mahato, Ram I

AU - Huang, Yongzhuo

PY - 2014/8/4

Y1 - 2014/8/4

N2 - Our objective was to design a polymeric micelle-based doxorubicin and lapatinib combination therapy for treating multidrug resistant (MDR) breast cancers. Poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonylpropylene carbonate) (PEG-PBC) polymers were synthesized for preparing doxorubicin and lapatinib loaded micelles using a film dispersion method. Micelles were characterized by determining critical micelle concentration (CMC), particle size distribution, and drug loading. The anticancer effects were determined in vitro with MTT assays as well as with lactate dehydrogenase (LDH) release studies. In addition, the cellular uptake of drug-loaded micelles was determined with fluorescence microscopy and flow cytometry. Finally, in vivo anticancer activity and tolerance of developed formulations were evaluated in resistant breast tumor bearing mice. PEG5K-PBC7K polymer synthesized in this study had a low CMC value (1.5 mg/L) indicating an excellent dynamic stability. PEG-PBC micelles could efficiently load both doxorubicin and lapatinib drugs with a loading density of 21% and 8.4%, respectively. The mean particle size of these micelles was 100 nm and was not affected by drug loading. The use of lapatinib as an adjuvant sensitized drug resistant MCF-7/ADR cells to doxorubicin treatment. Cellular uptake studies showed enhanced doxorubicin accumulation in MCF-7/ADR cells in the presence of lapatinib. The doxorubicin and lapatinib combination therapy showed a significant decrease in tumor growth compared to doxorubicin monotherapy. In conclusion, we have developed PEG-PBC micelle formulations for the delivery of doxorubicin and lapatinib. The combination therapy of doxorubicin plus lapatinib has a great potential for treating MDR breast cancer.

AB - Our objective was to design a polymeric micelle-based doxorubicin and lapatinib combination therapy for treating multidrug resistant (MDR) breast cancers. Poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonylpropylene carbonate) (PEG-PBC) polymers were synthesized for preparing doxorubicin and lapatinib loaded micelles using a film dispersion method. Micelles were characterized by determining critical micelle concentration (CMC), particle size distribution, and drug loading. The anticancer effects were determined in vitro with MTT assays as well as with lactate dehydrogenase (LDH) release studies. In addition, the cellular uptake of drug-loaded micelles was determined with fluorescence microscopy and flow cytometry. Finally, in vivo anticancer activity and tolerance of developed formulations were evaluated in resistant breast tumor bearing mice. PEG5K-PBC7K polymer synthesized in this study had a low CMC value (1.5 mg/L) indicating an excellent dynamic stability. PEG-PBC micelles could efficiently load both doxorubicin and lapatinib drugs with a loading density of 21% and 8.4%, respectively. The mean particle size of these micelles was 100 nm and was not affected by drug loading. The use of lapatinib as an adjuvant sensitized drug resistant MCF-7/ADR cells to doxorubicin treatment. Cellular uptake studies showed enhanced doxorubicin accumulation in MCF-7/ADR cells in the presence of lapatinib. The doxorubicin and lapatinib combination therapy showed a significant decrease in tumor growth compared to doxorubicin monotherapy. In conclusion, we have developed PEG-PBC micelle formulations for the delivery of doxorubicin and lapatinib. The combination therapy of doxorubicin plus lapatinib has a great potential for treating MDR breast cancer.

KW - breast cancer

KW - combination therapy

KW - doxorubicin

KW - lapatinib

KW - multidrug resistance

KW - nanomedicine

KW - polymeric micelles

UR - http://www.scopus.com/inward/record.url?scp=84905449941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905449941&partnerID=8YFLogxK

U2 - 10.1021/mp400687w

DO - 10.1021/mp400687w

M3 - Article

C2 - 24405470

AN - SCOPUS:84905449941

VL - 11

SP - 2600

EP - 2611

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 8

ER -